Jennifer F. Tseng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jennifer F. Tseng has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Sing Chau Ng
Surgical Outcomes Analysis and Research (SOAR), Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Rd, Palmer 6, Boston, MA, 02215, USA
18 shared publications- Mariam F. Eskander
Surgical Outcomes Analysis & Research, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
16 shared publications Mark P. Callery
Surgical Outcomes Analysis and Research (SOAR), Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Rd, Palmer 6, Boston, MA, 02215, USA
13 shared publicationsLindsay A. Bliss
Surgical Outcomes Analysis & Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
12 shared publicationsGyulnara G. Kasumova
Surgical Outcomes Analysis and Research (SOAR), Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Rd, Palmer 6, Boston, MA, 02215, USA
11 shared publicationsTara S. Kent
Surgical Outcomes Analysis and Research (SOAR), Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Rd, Palmer 6, Boston, MA, 02215, USA
11 shared publications
Latest Publications
- 4 October 2017
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 22 (2) , 214-225
Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study
- 4 October 2017
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 22 (2) , 214-225
Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study
Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review
BACKGROUND: The role of conventional radiotherapy in the management of pancreatic cancer has yet to be elucidated. Over the past decade, stereotactic body radiotherapy (SBRT) has emerged as a novel therapeutic option in pancreatic cancer care. This study evaluated the survival impact of SBRT on patients with unresected pancreatic cancer.METHODS: The National Cancer Data Base was queried for unresected patients who received chemotherapy for nonmetastatic pancreatic adenocarcinoma between 2004 and 2012. Four treatment groups were identified: chemotherapy alone, chemotherapy combined with external‐beam radiotherapy (EBRT), chemotherapy combined with intensity‐modulated radiotherapy (IMRT), and chemotherapy combined with SBRT. Propensity score models predicting the odds of receiving SBRT were created to control for potential selection bias, and patients were matched by propensity scores. The survival analysis was performed with the Kaplan‐Meier method.RESULTS: A total of 14,331 patients met the inclusion criteria. Chemotherapy alone was delivered to 5464 patients (38.1%); 6418 (44.8%), 322 (2.3%), and 2127 (14.8%) received chemotherapy along with EBRT, IMRT, and SBRT, respectively. The unadjusted median survival before matching was 9.9, 10.9, 12.0, and 13.9 months for patients treated with chemotherapy, EBRT, IMRT, and SBRT, respectively. In separate matched analyses, SBRT remained superior to chemotherapy alone (log‐rank P < .0001) and EBRT (log‐rank P = .0180). After matching, survival did not differ between patients receiving IMRT and patients receiving SBRT (log‐rank P = .0492).CONCLUSIONS: SBRT is associated with a significantly better outcome than chemotherapy alone or in conjunction with traditional EBRT. These results support the idea that SBRT is a promising treatment approach for patients with unresected pancreatic cancer. Cancer 2017;123:4158–4167. © 2017 American Cancer Society.
Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review
BACKGROUND: The role of conventional radiotherapy in the management of pancreatic cancer has yet to be elucidated. Over the past decade, stereotactic body radiotherapy (SBRT) has emerged as a novel therapeutic option in pancreatic cancer care. This study evaluated the survival impact of SBRT on patients with unresected pancreatic cancer.METHODS: The National Cancer Data Base was queried for unresected patients who received chemotherapy for nonmetastatic pancreatic adenocarcinoma between 2004 and 2012. Four treatment groups were identified: chemotherapy alone, chemotherapy combined with external‐beam radiotherapy (EBRT), chemotherapy combined with intensity‐modulated radiotherapy (IMRT), and chemotherapy combined with SBRT. Propensity score models predicting the odds of receiving SBRT were created to control for potential selection bias, and patients were matched by propensity scores. The survival analysis was performed with the Kaplan‐Meier method.RESULTS: A total of 14,331 patients met the inclusion criteria. Chemotherapy alone was delivered to 5464 patients (38.1%); 6418 (44.8%), 322 (2.3%), and 2127 (14.8%) received chemotherapy along with EBRT, IMRT, and SBRT, respectively. The unadjusted median survival before matching was 9.9, 10.9, 12.0, and 13.9 months for patients treated with chemotherapy, EBRT, IMRT, and SBRT, respectively. In separate matched analyses, SBRT remained superior to chemotherapy alone (log‐rank P < .0001) and EBRT (log‐rank P = .0180). After matching, survival did not differ between patients receiving IMRT and patients receiving SBRT (log‐rank P = .0492).CONCLUSIONS: SBRT is associated with a significantly better outcome than chemotherapy alone or in conjunction with traditional EBRT. These results support the idea that SBRT is a promising treatment approach for patients with unresected pancreatic cancer. Cancer 2017;123:4158–4167. © 2017 American Cancer Society.
- 1 June 2017
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 224 (6) , 1057-1064
National Rise of Primary Pancreatic Carcinoid Tumors: Comparison to Functional and Nonfunctional Pancreatic Neuroendocrine Tumors
New guidelines recommend differentiating between carcinoid and pancreatic neuroendocrine tumors (PNETs) during clinical trials. However, little is known about the behavior and incidence of primary pancreatic carcinoid tumors. We performed a retrospective cohort study using the National Cancer Data Base (NCDB) to identify adults with primary PNETs diagnosed between 2004 and 2013. The Kaplan-Meier method was used to evaluate overall survival, and multivariate Cox proportional hazards model was used to assess the hazard of death in resected patients. Of 10,752 patients, 12.7% were diagnosed with carcinoid tumors, 84.7% with nonfunctional and 2.6% with functional PNETs. Although the number of functional PNETs has remained relatively constant over time, rates of nonfunctional and carcinoid tumors have risen dramatically. Only 36 (5.7%) carcinoid tumors were diagnosed in 2004; this increased to 497 (27.7%) in 2013. Overall survival was significantly longer for carcinoid compared with functional and nonfunctional tumors (log-rank p < 0.0001), with 5-year survival rates of 63.1%, 58.3%, and 52.6%, respectively. For patients having resection, overall survival further improved for carcinoid tumors relative to functional (log-rank p = 0.0011) and nonfunctional (log-rank p < 0.0001) tumors, but the survival difference between functional and nonfunctional tumors disappeared (log-rank p = 0.4579); 5-year survival rates were 89.2%, 76.6%, and 78.7%, respectively. On multivariate Cox regression of the resected cohort, mortality was significantly higher for patients with functional (hazard ratio [HR] 1.81) and nonfunctional (HR 1.40) PNETs compared with carcinoid tumors. Primary pancreatic carcinoid tumors are increasingly being diagnosed. Differentiating PNET subtypes plays an important role in prognostication. Resection remains a critical component of care.
- 1 June 2017
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 224 (6) , 1057-1064
National Rise of Primary Pancreatic Carcinoid Tumors: Comparison to Functional and Nonfunctional Pancreatic Neuroendocrine Tumors
New guidelines recommend differentiating between carcinoid and pancreatic neuroendocrine tumors (PNETs) during clinical trials. However, little is known about the behavior and incidence of primary pancreatic carcinoid tumors. We performed a retrospective cohort study using the National Cancer Data Base (NCDB) to identify adults with primary PNETs diagnosed between 2004 and 2013. The Kaplan-Meier method was used to evaluate overall survival, and multivariate Cox proportional hazards model was used to assess the hazard of death in resected patients. Of 10,752 patients, 12.7% were diagnosed with carcinoid tumors, 84.7% with nonfunctional and 2.6% with functional PNETs. Although the number of functional PNETs has remained relatively constant over time, rates of nonfunctional and carcinoid tumors have risen dramatically. Only 36 (5.7%) carcinoid tumors were diagnosed in 2004; this increased to 497 (27.7%) in 2013. Overall survival was significantly longer for carcinoid compared with functional and nonfunctional tumors (log-rank p < 0.0001), with 5-year survival rates of 63.1%, 58.3%, and 52.6%, respectively. For patients having resection, overall survival further improved for carcinoid tumors relative to functional (log-rank p = 0.0011) and nonfunctional (log-rank p < 0.0001) tumors, but the survival difference between functional and nonfunctional tumors disappeared (log-rank p = 0.4579); 5-year survival rates were 89.2%, 76.6%, and 78.7%, respectively. On multivariate Cox regression of the resected cohort, mortality was significantly higher for patients with functional (hazard ratio [HR] 1.81) and nonfunctional (HR 1.40) PNETs compared with carcinoid tumors. Primary pancreatic carcinoid tumors are increasingly being diagnosed. Differentiating PNET subtypes plays an important role in prognostication. Resection remains a critical component of care.
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S902
Impact of Treatments on Diabetic Control and Gastrointestinal Symptoms after Total Pancreatectomy
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S902
Impact of Treatments on Diabetic Control and Gastrointestinal Symptoms after Total Pancreatectomy
- 19 March 2017
- Published by Springer Nature
- p. 277-288
Pancreatic Adenocarcinoma in the Head of the Pancreas with Portal Vein Involvement
- 19 March 2017
- Published by Springer Nature
- p. 277-288
Pancreatic Adenocarcinoma in the Head of the Pancreas with Portal Vein Involvement
- 23 November 2016
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 25 (1) , 51-58
The Role of Venous and Arterial Resection in Pancreatic Cancer Surgery
Pancreatic cancer continues to carry a dismal prognosis with the majority of patients presenting at advanced stages of disease. Complete surgical resection remains essential for prolonging survival and increasing the possibility of cure. However, few patients will be resectable at diagnosis, with a significant portion presenting with borderline or locally advanced disease. The addition of vascular resection and reconstruction at the time of pancreatectomy enables expansion of the patient population able to undergo resection with curative intent and achieve tumor-free margins. This review provides an overview of the literature regarding the role of venous and arterial resection in the treatment of pancreatic cancer, with a focus on outcomes including survival, morbidity, and mortality.
- 23 November 2016
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 25 (1) , 51-58
The Role of Venous and Arterial Resection in Pancreatic Cancer Surgery
Pancreatic cancer continues to carry a dismal prognosis with the majority of patients presenting at advanced stages of disease. Complete surgical resection remains essential for prolonging survival and increasing the possibility of cure. However, few patients will be resectable at diagnosis, with a significant portion presenting with borderline or locally advanced disease. The addition of vascular resection and reconstruction at the time of pancreatectomy enables expansion of the patient population able to undergo resection with curative intent and achieve tumor-free margins. This review provides an overview of the literature regarding the role of venous and arterial resection in the treatment of pancreatic cancer, with a focus on outcomes including survival, morbidity, and mortality.